Mount Sinai Innovation Partners Mount Sinai Innovation Partners Mount Sinai Innovation Partners Mount Sinai Innovation Partners
  • Get Started
    • Disclose a Technology
    • Request an Agreement
    • Search Technologies
    • Contact Your Representative
  • About Us
    • Our Mission
    • Our Impact
      • Technologies
      • Startup Companies
    • Our Team
    • Our Partners
  • Programs
    • Elementa Labs
    • Entrepreneurship Program
    • Fellows Program
    • i3 Funding
      • i3 Prism
      • i3 Genesis
      • i3 Accelerator
    • External Collaborations
  • Resources
    • Innovation Guide
    • Drug Discovery Guide
    • Local Resources
    • Institutional Policies
    • Frequently Asked Questions (FAQs)
  • Discover More
    • News
    • Events
    • Videos
  • Careers
    • Explore Career Opportunities
  • Mount Sinai Health System
    • MountSinai.org
    • Search Faculty
    • Clinical Trials
    • Donations & Gifts
    • Faculty Consulting
Diagnostic

GENE-SIGNATURE FOR DIAGNOSIS OF EARLY HEPATOCELLULAR CARCINOMA

September 22, 2015

The incidence of hepatocellular carcinoma (HCC) is 750,000 new cases globally, it is the second leading cause of cancer-related death and represents a major health problem. When identified at early stages, curative treatments such as resection, transplantation and percutaneous ablation are feasible. …

Read full post
Diagnostic

SLICE-SELECTIVE ADIABATIC MAGNETIZATION PREPARATION (SAMPA) FOR T2-WEIGHTED AND DIFFUSION-WEIGHTED IMAGING

August 11, 2015

Magnetic resonance (MR) imaging at high-fields (3-4.7T) and ultra-high fields (7T and above) leads to higher signal levels with improved image quality, but physical limitations still prevent these systems from being highly efficient.  The gold standard for an important MRI method such …

Read full post
Diagnostic

SEMI-ADIABATIC SPECTRAL-SPATIAL SPECTROSCOPIC IMAGING (SASSI)

August 11, 2015

Proton magnetic resonance spectroscopic imaging (MRSI) can be used as a non-invasive technique for a variety of procedures such as differentiating radiation damage from brain tumors post-therapy, categorizing brain tumors, or investigating neurological and psychiatric diseases like Alzheimer’s and Parkinson’s Disease. However, …

Read full post
Diagnostic

IDENTIFYING THE SUBTYPES OF LEUKEMIA BY CHARACTERIZING THE MUTATIONS OF THE PTPN11 GENE

February 25, 2015

Intracellular signaling pathways mediate cellular responses to a variety of extracellular signals and dysregulation of such pathways, especially those involved in cell growth and differentiation, is the main cause of cancer. The RAS family of proteins plays key roles in signal transduction, …

Read full post
Diagnostic

A SET OF 3 URINARY BIOMARKERS AS A PROGNOSTIC/DIAGNOSTIC FOR KIDNEY DISEASE

June 19, 2014

This technology relates to the use of 3 biomarkers present in urine that can be used to predict kidney disease progression. Briefly, Dr. Böttinger and colleagues have discovered a set of 3 biomarkers that can be used over time to determine the …

Read full post
Diagnostic

RoSE Scale (Recognition of Smile Excursion)

May 29, 2014

At the Mount Sinai Medical Center, Drs. Elliott Rose, Peter Taub, Eric Jablonka and Ilya Shnaydman have developed the digitally based RoSE Facial Grading System software program for portable tablets (iPads) and computers to objectively measure smile (facial expression) symmetry in the …

Read full post
Diagnostic

A VERSATILE IN VIVO RNA-INTERFERENCE DELIVERY PLATFORM

May 14, 2014

The ability to deliver miRNAs or small interfering RNAs (siRNAs) in vivo has been a major hurdle in harnessing the power of RNA interference. This platform technology employs RNA virus-like vectors to deliver functional small RNAs to any tissue of interest. Depending …

Read full post
Diagnostic

MODIFIED VERO CELLS WITH SUPPRESSED INNATE IMMUNE RESPONSES AND ENHANCED VIRUS PRODUCTION

May 12, 2014

Dr. Chris Basler and colleagues have developed a stable cell line with enhanced virus replication and production efficiency. The Vero 76 cell line (ATCC No. CCL-1587) has been widely used for cell-based research and product development (1, 2, 4). Several characteristics of …

Read full post
Diagnostic

PLATELET-DERIVED GROWTH FACTOR RECEPTOR BETA AND NOTCH3 RECEPTOR MODULATORS FOR THE TREATMENT OF INFANTILE MYOFIBROMATOSIS

April 24, 2014

Infantile myofibromatosis (IMF) is one of the most common proliferative fibrous tumors of infancy and childhood. IMF is a disorder of mesenchymal proliferation characterized by the development of non-metastasizing tumors in the skin, muscle, bone and viscera. Occurrence within families across multiple …

Read full post

Mount Sinai Health System

The Mount Sinai Health System is an integrated health care system providing exceptional medical care to our local and global communities.

Read More

Contact MSIP

MSIPInfo@mssm.edu

For technology and research inquiries: visit Contact Your Representative or Contact MSIP

 

Follow Us

  • LinkedIn
  • Facebook
  • X
  • YouTube

Stay Updated

Sign up for the MSIP mailing list

Mount Sinai Innovation Partners © Copyright 2025

  • Privacy Policy
  • Terms & Conditions
  • Non-Discrimination Notice
  • Get Started
    • Disclose a Technology
    • Request an Agreement
    • Search Technologies
    • Contact Your Representative
  • About Us
    • Our Mission
    • Our Impact
      • Technologies
      • Startup Companies
    • Our Team
    • Our Partners
  • Programs
    • Elementa Labs
    • Entrepreneurship Program
    • Fellows Program
    • i3 Funding
      • i3 Prism
      • i3 Genesis
      • i3 Accelerator
    • External Collaborations
  • Resources
    • Innovation Guide
    • Drug Discovery Guide
    • Local Resources
    • Institutional Policies
    • Frequently Asked Questions (FAQs)
  • Discover More
    • News
    • Events
    • Videos
  • Careers
    • Explore Career Opportunities
  • Mount Sinai Health System
    • MountSinai.org
    • Search Faculty
    • Clinical Trials
    • Donations & Gifts
    • Faculty Consulting

Hit enter to search or ESC to close